Deliverable 3.4: National Development Plans for Data Services in Non-CESSDA Member Countries in the ERA

This deliverable contains the second output of task 3.3 – national development plans for establishing data services in the social sciences in non-CESSDA member countries in Europe. The goal of task 3.3 of CESSDA SaW was to draw up individual national development plans for aspiring CESSDA Service Providers. In total, NDPs have been developed in 13 countries. Nine NDPs are included in this deliverable, while four are still pending approval from national authorities and/or local potential host institutions

Znaczenie stężenia NT-proBNP w określaniu rokowania i ocenie diagnostycznej u chorych z ostrymi zespołami wieńcowymi

Background and aim: N terminal-proB-type natriuretic peptide (NT-proBNP) is synthesised and secreted from the ventricularmyocardium. This marker is known to be elevated in patients with acute coronary syndromes (ACS). We evaluated NT-proBNP asa significant diagnostic marker and an important independent predictor of short-term mortality (one month) in patients with ACS.Methods: NT-proBNP and cardiac troponin I (cTI) were assessed in 134 consecutive patients (median age 66 years, 73% male)hospitalised for ACS in a cardiological university department. The patients were classified into ST-elevation ACS (STE-ACS, n = 74) and non-ST-elevation ACS (NSTE-ACS, n = 60) groups based on the ECG findings on admission. Patients with Killipclass ≥ II were excluded.Results: The serum level of NT-proBNP on admission was significantly higher (p < 0.0005), while there was no differencein cTI serum level in the NSTE-ACS patients compared to STE-ACS patients. There was a significant positive correlation betweenNT-proBNP and cTI in the NSTE-ACS (r = 0.338, p = 0.008) and STE-ACS (r = 0.441, p < 0.0005) patients. Therewas a significant difference in NT-proBNP (p < 0.0005) and cTI (p < 0.0005) serum level between ACS patients who diedwithin 30 days or who survived after one month. The increased NT-proBNP level is the strongest predictor of mortality in ACSpatients, also NT-proBNP cut-point level of 1,490 pg/mL is a significant independent predictor of mortality.Conclusions: We demonstrated the differences and the correlation in the secretion of NT-proBNP and cTI in patients withSTE-ACS vs. NSTE-ACS. Our results provide evidence that NT-proBNP is a significant diagnostic marker and an importantindependent predictor of short-term mortality in patients with ACS.Wstęp i cel: N-końcowy fragment propeptydu natriuretycznego typu B (NT-proBNP) jest syntetyzowany i wydzielany przezmiokardium komór serca. Wiadomo, że stężenie tego wskaźnika jest podwyższone u chorych z ostrymi zespołami wieńcowymi (ACS). Autorzy ocenili znaczenie stężenia NT-proBNP jako istotnego wskaźnika diagnostycznego i ważnego niezależnegoczynnika prognostycznego śmiertelności krótkoterminowej (w ciągu 1 miesiąca) u chorych z ACS.Metody: Oznaczono stężenia NT-proBNP i sercowej troponiny I (cTI) u 134 kolejnych chorych (mediana wieku 66 lat, 73%mężczyzn) hospitalizowanych z powodu ACS na oddziale kardiologicznym szpitala uniwersyteckiego. Pacjentów przydzielanodo grupy ACS z uniesieniem odcinka ST (STE-ACS, n = 74) lub do grupy ACS bez uniesienia odcinka ST (NSTE-ACS, n = 60)na podstawie EKG wykonanego przy przyjęciu. Chorych w klasie Killipa ≥ II wykluczono z badania.Wyniki: Stężenie NT-proBNP w surowicy przy przyjęciu do szpitala było istotnie wyższe (p < 0,0005) u pacjentów z NSTE--ACS niż u osób z STE-ACS, natomiast surowicze stężenia cTI były podobne w obu grupach. Stwierdzono istotną dodatniąkorelację między stężeniami NT-proBNP i cTI u chorych z NSTE-ACS (r = 0,338; p = 0,008) i u osób z STE-ACS (r = 0,441;p < 0,0005). Stężenia NT-proBNP (p < 0,0005) i cTI (p < 0,0005) w surowicy różniły się istotnie między chorymi z ACS,którzy zmarli w ciągu 30 dni, a pacjentami, którzy żyli dłużej niż miesiąc. Zwiększone stężenie NT-proBNP jest najsilniejszymczynnikiem prognostycznym zgonu u chorych z ACS. Ponadto stężenie NT-proBNP powyżej progowej wartości 1490 pg/mL jest istotnym niezależnym czynnikiem prognostycznym zgonu.Wnioski: Autorzy wykazali różnice w wydzielaniu NT-proBNP i cTI między chorymi ze STE-ACS i chorymi z NSTE-ACS orazkorelacje między tymi wskaźnikami. Uzyskane przez nich wyniki dowodzą, że NT-proBNP jest istotnym niezależnym wskaźnikiemdiagnostycznym i ważnym niezależnym czynnikiem prognostycznym śmiertelności krótkoterminowej u chorych z ACS

The effects of combined physical procedures on the functional status of patients with diabetic polyneuropathy

Background/Aim. Diabetic polyneuropathy is a common chronic complication in patients with diabetes mellitus. The aim of this study was to determine the importance of applied physical procedures on the functional status of diabetic polyneuropathy patients compared to the group of respondents treated by alpha-lipoic acid. Methods. Sixty subjects were divided into two groups: group A – diabetic polyneuropathy patients treated with physical procedures, and group B – diabetic polyneuropathy patients treated with alpha-lipoic acid. The study has lasted for three diagnostic and therapeutic cycles, each lasting for 16 days with a time between cycles of 6 weeks. Results. Manual muscle test, range of motion, Michigan Neuropathy Screening Instrument, and Berg balance scale values showed statistically significant improvement at the end of testing group A respondents, while no improvement was shown in group B respondents. Conclusion. The application of the combined physical procedures shows clear benefits for the improvement of muscle strength and mobility of the ankle joint in respondents with diabetic polyneuropathy

Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma

Background and Objectives. The aim of the study was to determine systemic and fecal values of galectin-3 and pro- and anti-inflammatory cytokines in patients with CRC and the relationship with clinicopathological aspects. Methods. Concentrations of galectin-3, TNF-α, TGF-β, IL-10, and IL-1β were analyzed in samples of blood and stool of 60 patients with CRC. Results. Systemic concentration of TNF-α was significantly lower in patients with severe diseases (advanced TNM stage, nuclear grade, and poor histological differentiation) as in patients with more progressive CRC (lymph and blood vessel invasion, presence of metastasis). Fecal values of anti-inflammatory cytokines TGF-β and IL-10 were increased in patients with severe stadium of CRC. Fecal concentration of Gal-3 was enhanced in CRC patients with higher nuclear grade, poor tumor tissue differentiation, advanced TNM stage, and metastatic disease. Gal-3/TNF-α ratio in sera and feces had a higher trend in patients with severe and advanced diseases. Positive correlation between fecal Gal-3 and disease severity, tumor progression, and biomarkers AFP and CEA, respectively, was also observed. Conclusions. Predomination of Gal-3 in patients with advanced diseases may implicate on its role in limiting ongoing proinflammatory processes. The fecal values of Gal-3 can be used as a valuable marker for CRC severity and progression